Education
About Us
Working with TipRanks
Follow Us
Rxsight, Inc. (RXST)
:RXST
RXST Stock Chart & Stats
$9.73
-$1.16(-3.26%)
At close: 4:00 PM EST
$9.73
-$1.16(-3.26%)
Day’s Range― - ―
52-Week Range$6.32 - $47.89
Previous CloseN/A
Volume110.15K
Average Volume (3M)720.84K
Market Cap
$400.06M
Enterprise Value$152.33M
Total Cash (Recent Filing)$227.52M
Total Debt (Recent Filing)$11.56M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 10, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding41,116,640
10 Day Avg. Volume953,976
30 Day Avg. Volume720,838
Financial Highlights & Ratios
PEG Ratio0.98
Price to Book (P/B)4.75
Price to Sales (P/S)9.55
P/FCF Ratio-59.69
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue1.07
Enterprise Value/Gross Profit1.43
Enterprise Value/Ebitda-4.66
Forecast
1Y Price Target
$9.60Price Target Upside-1.34% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-1.21
Revenue Forecast (FY)$125.49M
Bulls Say, Bears Say
Bulls Say
Demographic ShiftsManagement highlighted encouraging demographic shifts, including a younger cataract patient population who tend to be more sensitive to quality of vision issues.
Revenue GrowthRXST's 3Q25 revenue beat consensus and management raised the mid-point of its guidance.
Strategic InitiativesManagement noted a more strategic approach to LDD placements with a greater focus on driving LAL volumes through engagement initiatives.
Bears Say
Guidance ReductionRXST lowered its fiscal year guidance and now expects revenue in the range of $120.0M- $130.0M, which is a decrease from the previous range.
Revenue UnderperformanceRXST reported revenue of $33.6M, which was below initial consensus estimates and BTIG's estimate.
Valuation ConcernsGiven RXST's valuation, the analyst reiterates a Buy rating but lowers the price target to $11 (from $22 prior).
RxSight News
RXST FAQ
What was Rxsight, Inc.’s price range in the past 12 months?
Rxsight, Inc. lowest stock price was $6.32 and its highest was $47.89 in the past 12 months.
What is Rxsight, Inc.’s market cap?
Rxsight, Inc.’s market cap is $400.06M.
When is Rxsight, Inc.’s upcoming earnings report date?
Rxsight, Inc.’s upcoming earnings report date is Mar 10, 2026 which is in 113 days.
How were Rxsight, Inc.’s earnings last quarter?
Rxsight, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.376 by $0.136.
Is Rxsight, Inc. overvalued?
According to Wall Street analysts Rxsight, Inc.’s price is currently Overvalued.
Does Rxsight, Inc. pay dividends?
Rxsight, Inc. does not currently pay dividends.
What is Rxsight, Inc.’s EPS estimate?
Rxsight, Inc.’s EPS estimate is -0.34.
How many shares outstanding does Rxsight, Inc. have?
Rxsight, Inc. has 41,116,640 shares outstanding.
What happened to Rxsight, Inc.’s price movement after its last earnings report?
Rxsight, Inc. reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.376. Following the earnings report the stock price went up 3.237%.
Which hedge fund is a major shareholder of Rxsight, Inc.?
Currently, no hedge funds are holding shares in RXST
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.60 (-1.34% Downside)
$9.60 (-1.34% Downside)
Blogger Sentiment
Bullish
RXST Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 760.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.96%
12-Months-Change
Fundamentals
Return on Equity
-12.92%
Trailing 12-Months
Asset Growth
-0.62%
Trailing 12-Months
Company Description
Rxsight, Inc.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While RxSight has made strides in improving its gross margin and increasing LAL revenue, the company faced significant challenges with overall revenue decline and a substantial decrease in LDD sales. The global expansion efforts and positive market reception of the Light Adjustable Lens are promising, but the increased net loss and revenue challenges present concerns.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$9.60
▼(-1.34% Downside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Butterfly Network
―
NeuroPace
―
Ceribell, Inc.
―
Ownership Overview
5.63% Insiders
16.86% Mutual Funds
0.16% Other Institutional Investors
62.09% Public Companies and
Individual Investors